Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 4/2005

01-08-2005 | Review

Imaging in breast cancer: Magnetic resonance spectroscopy

Authors: Patrick J Bolan, Michael T Nelson, Douglas Yee, Michael Garwood

Published in: Breast Cancer Research | Issue 4/2005

Login to get access

Abstract

A technique called in vivo magnetic resonance spectroscopy (MRS) can be performed along with magnetic resonance imaging (MRI) to obtain information about the chemical content of breast lesions. This information can be used for several clinical applications, such as monitoring the response to cancer therapies and improving the accuracy of lesion diagnosis. Initial MRS studies of breast cancer show promising results, and a growing number of research groups are incorporating the technique into their breast MRI protocols. This article introduces 1H-MRS of the breast, reviews the literature, discusses current methods and technical issues, and describes applications for treatment monitoring and lesion diagnosis.
Appendix
Available only for authorised users
Literature
1.
Daly PF, Cohen JS: Magnetic resonance spectroscopy of tumors and potential in vivo clinical applications: a review. Cancer Res. 1989, 49: 770-779.PubMed
2.
Leach MO, Verrill M, Glaholm J, Smith TAD, Collins DJ, Payne GS, Sharp JC, Ronen SM, McCready VR, Powles TJ, et al: Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurement and a report of localized 31P measurements of response to treatment. NMR Biomed. 1998, 11: 314-340. 10.1002/(SICI)1099-1492(1998110)11:7<314::AID-NBM522>3.0.CO;2-Z.CrossRefPubMed
3.
Sijens PE, Wijrdeman HK, Moerland MA, Bakker CJG, Vermeulen JWAH, Luyten PR: Human breast cancer in vivo: H-1 and P-31 MR spectroscopy at 1.5 T. Radiology. 1988, 169: 615-620.CrossRefPubMed
4.
Jagannathan NR, Singh M, Govindaraju V, Raghunathan P, Choshic O, Julka PK, Rath GK: Volume localized in vivo proton MR spectroscopy of breast carcinoma: variation of water-fat ratio in patients receiving chemotherapy. NMR Biomed. 1998, 11: 414-422. 10.1002/(SICI)1099-1492(199812)11:8<414::AID-NBM537>3.0.CO;2-W.CrossRefPubMed
5.
Thomas MA, Binesh N, Yue K, DeBruhl N: Volume-localized two-dimensional correlated magnetic resonance spectroscopy of human breast cancer. J Magn Reson Imaging. 2001, 14: 181-186. 10.1002/jmri.1170.CrossRefPubMed
6.
Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE: Human breast lesions: characterization with proton MR spectroscopy. Radiology. 1998, 209: 269-275.CrossRefPubMed
7.
Gribbestad IS, Singstad TE, Nilsen G, Fjosne HE, Engan T, Haugen OA, Rinck PA: In vivo 1H MRS of normal breast and breast tumors using dedicated double breast coil. J Magn Reson Imaging. 1998, 8: 1191-1197.CrossRefPubMed
8.
Kvistad KA, Bakken IJ, Gribbestad IS, Ehrnholm B, Lundgren S, Fjosne HE, Haraldseth O: Characterization of neoplastic and normal human breast tissues with in vivo 1H MR spectroscopy. J Magn Reson Imaging. 1999, 10: 159-164. 10.1002/(SICI)1522-2586(199908)10:2<159::AID-JMRI8>3.0.CO;2-0.CrossRefPubMed
9.
Yeung DK, Cheung HS, Tse GM: Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy – initial results. Radiology. 2001, 220: 40-46.CrossRefPubMed
10.
Cecil KM, Schnall MD, Siegelman ES, Lenkinski RE: The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy. Breast Cancer Res Treat. 2001, 68: 45-54. 10.1023/A:1017911211090.CrossRefPubMed
11.
Jagannathan NR, Kumar M, Seenu V, Coshic O, Dwivedi SN, Julka PK, Srivastava A, Rath GK: Evaluation of total choline from in vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer. 2001, 84: 1016-1022. 10.1054/bjoc.2000.1711.CrossRefPubMedPubMedCentral
12.
Mackinnon WB, Barry PA, Malycha PL, Gillett DJ, Russell P, Lean CL, Doran ST, Barraclough BH, Bilous M, Mountford CE: Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology. 1997, 204: 661-666.CrossRefPubMed
13.
Cheng LL, Chang W, Smith BL, Gonzalez RG: Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectrscopy. J Magn Reson. 1998, 135: 194-202. 10.1006/jmre.1998.1578.CrossRefPubMed
14.
Gribbestad IS, Sitter B, Lundgren S, Krane J, Axelson D: Metabolite composition in breast tumors examined by proton nuclear magnetic resonance spectroscopy. Anticancer Res. 1999, 19: 1737-1746.PubMed
15.
Garwood M, DelaBarre L: The return of the frequency sweep: designing adiabatic pulses for contemporary NMR. J Magn Reson. 2001, 153: 155-177. 10.1006/jmre.2001.2340.CrossRefPubMed
16.
Jacobs MA, Barker PB, Bottomley PA, Bhujwalla Z, Bluemke DA: Proton magnetic resonance spectroscopic imaging of human breast cancer: a preliminary study. J Magn Reson Imaging. 2004, 19: 68-75. 10.1002/jmri.10427.CrossRefPubMed
17.
Bolan PJ, DelaBarre L, Baker EH, Merkle H, Everson LI, Yee D, Garwood M: Eliminating spurious lipid sidebands in 1H MRS of breast lesions. Magn Reson Med. 2002, 48: 215-222. 10.1002/mrm.10224.CrossRefPubMed
18.
Bolan PJ, Meisamy S, Baker EH, Lin J, Emory T, Nelson M, Everson LI, Yee D, Garwood M: In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn Reson Med. 2003, 50: 1134-1143. 10.1002/mrm.10654.CrossRefPubMed
19.
Bakken IJ, Gribbestad IS, Singstad TE, Kvistad KA: External standard method for the in vivo quantification of choline-containing compounds in breast tumors by proton MR spectroscopy at 1.5 Tesla. Magn Reson Med. 2001, 46: 189-192. 10.1002/mrm.1175.CrossRefPubMed
20.
Katz-Brull R, Lavin PT, Lenkinski RE: Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst. 2002, 94: 1197-1203.CrossRefPubMed
21.
Huang W, Fisher PR, Dulaimy K, Tudorica LA, O'Hea B, Button TM: Detection of breast malignancy: diagnostic MR protocol for improved specificity. Radiology. 2004, 232: 585-591.CrossRefPubMed
22.
Meisamy S, Bolan PJ, Baker EH, Pollema MG, Le CT, Kelcz F, Lechner MC, Luikens BA, Carlson RA, Brandt KR, et al: The value of adding quantitative 1H MRS for improving diagnostic accuracy of breast MRI: preliminary results from an observer performance study at 4 Tesla. Radiology. 2005,
23.
Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, Nelson MT, Emory TH, Tuttle TM, Yee D, et al: Predicting response to neoadjuvant chemotherapy of locally advanced breast cancer with in vivo 1H MRS: a pilot study at 4 Tesla. Radiology. 2004, 233: 424-431.CrossRefPubMed
24.
Kim J-K, Park S-H, Lee HM, Lee Y-H, Sung N-K, Chung D-S, Kim O-D: In vivo 1H-MRS evaluation of malignant and benign breast disease. Breast. 2003, 12: 179-182. 10.1016/S0960-9776(03)00012-2.CrossRefPubMed
25.
Tse GMK, Cheung HS, Pang L-M, Chu WCW, Law BKB, Kung FYL, Yeung DKW: Characterization of lesions of the breast with proton MR spectroscopy: comparison of carcinomas, benign lesions, and phyllodes tumors. Am J Roentgenol. 2003, 181: 1267-1272.CrossRef
Metadata
Title
Imaging in breast cancer: Magnetic resonance spectroscopy
Authors
Patrick J Bolan
Michael T Nelson
Douglas Yee
Michael Garwood
Publication date
01-08-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 4/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1202

Other articles of this Issue 4/2005

Breast Cancer Research 4/2005 Go to the issue

Erratum

Erratum to: Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study

Research article

Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2

Research article

Effects of milk fermented by Lactobacillus helveticusR389 on a murine breast cancer model

Research article

Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells

Research article

Mutation analysis of the ATRgene in breast and ovarian cancer families

Research article

Genetic polymorphisms in the matrix metalloproteinase 12 gene (MMP12) and breast cancer risk and survival: the Shanghai Breast Cancer Study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits